Phase 4 Psoriasis Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with moderate-to-severe plaque psoriasis by a dermatologist or other qualified clinician experienced in treating psoriasis
• People with a body mass index (BMI) of 30 or above (classified as obese), or a BMI between 27 and under 30 (classified as overweight) alongside at least one weight-related health condition such as high blood pressure, abnormal cholesterol levels, type 2 diabetes, obstructive sleep apnea, or heart/cardiovascular disease
• People who started treatment with ixekizumab approximately 3 months before the decision to add the second study medication (within a window of 2 to 4 months)
• People who are able to begin the second study medication within 30 days of the initial screening visit

Who may not be able to join:

• People who have been receiving ixekizumab for more than 4 months or less than 2 months at the time of the decision to add the second medication
• People who have previously used tirzepatide or similar medications known as GLP-1 receptor agonists, such as dulaglutide, liraglutide, or semaglutide
• People who are currently participating in another clinical trial
• People with a known allergy or sensitivity to tirzepatide or any of its ingredients
• People with a personal or family history of a specific type of thyroid cancer called medullary thyroid cancer
• People with a condition called multiple endocrine neoplasia type 2 (a rare hormonal disorder)
• People with type 1 diabetes
• People who have had inflammation of the pancreas (pancreatitis), either in the past or currently
• People with certain serious eye complications related to diabetes, including proliferative diabetic retinopathy, diabetic maculopathy, or a form of nonproliferative diabetic retinopathy that requires immediate treatment
• People with a history of a dangerous condition called diabetic ketoacidosis or a hyperosmolar state/coma (serious diabetes-related emergencies)
• People who have experienced severe low blood sugar episodes or who are unaware when their blood sugar drops dangerously low, within the 6 months before screening
• People with a history of serious stomach or digestive problems, including delayed stomach emptying (gastroparesis), severe acid reflux, persistent indigestion, or chronic nausea, constipation, or vomiting

Important: Always verify eligibility with the trial site directly before applying.